A. Bitton

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
A Bitton, A. Bitton, Alain M. Bitton, Alain Bitton
Publication record
375 papers · 21,821 citations · H-index 64

PAPERS

Assessing the role of ustekinumab dose escalation in Crohn’s disease patients with loss of response: an observational study
20250 citationsauthor #3
Clinical outcomes and drug sustainability after non-medical switch from ustekinumab originator to biosimilars in inflammatory bowel disease
20250 citationsauthor #6
Sa1839 MAGIC IN IMAGINE COHORT: THE USE OF PRESCRIPTION DRUGS, COMPLEMENTARY AND ALTERNATIVE THERAPIES, SMOKING, MARIJUANA, AND ALCOHOL PER CROHN'S DISEASE PHENOTYPES IN A LARGE CANADIAN COHORT
20230 citationsauthor #13
Hospitalization Rates for Inflammatory Bowel Disease Are Decreasing Over Time: A Population-based Cohort Study
20237 citationsauthor #10
Comparative performances of machine learning methods for classifying Crohn Disease patients using genome-wide genotyping data
20230 citationsauthor #64
Mo1728 ASSOCIATION BETWEEN SERUM USTEKINUMAB CONCENTRATIONS AND ENDOSCOPIC DISEASE ACTIVITY IN CROHN'S DISEASE
20230 citationsauthor #7
Serum Lipidomic Screen Identifies Key Metabolites, Pathways, and Disease Classifiers in Crohn's Disease.
202317 citationsauthor #5
P417 Frequent Early Nocebo Complaints but Maintained Clinical Efficacy, Biomarker and Therapeutic drug levels following mandatory Biosimilar Switch in Patients with Inflammatory Bowel disease: Preliminary data from a Prospective Observational Cohort Study
20231 citationsauthor #8
Sa1776 THE CURRENT AND FUTURE BURDEN OF HOSPITALIZATIONS FOR INFLAMMATORY BOWEL DISEASE: A CANADIAN NATION-WIDE ANALYSIS
20230 citationsauthor #6
Sa1773 FORECASTING THE INCIDENCE AND PREVALENCE OF INFLAMMATORY BOWEL DISEASE: A NATION-WIDE ANALYSIS
20230 citationsauthor #5
The 2023 Impact of Inflammatory Bowel Disease in Canada: Executive Summary
202323 citationsauthor #4
Tu1777 FREQUENT EARLY NOCEBO COMPLAINTS BUT MAINTAINED CLINICAL EFFICACY, BIOMARKER AND THERAPEUTIC DRUG LEVELS FOLLOWING MANDATORY BIOSIMILAR SWITCH IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
20230 citationsauthor #5
A189 EMERGENCY DEPARTMENT UTILIZATION AND RISK OF INTESTINAL RESECTION IS LOWER AMONG CHILDREN DIAGNOSED WITH INFLAMMATORY BOWEL DISEASE BEFORE 10 YEARS OF AGE: A MULTIPROVINCE POPULATION-BASED COHORT STUDY
20230 citationsauthor #3
A183 VARIATION IN HEALTH SERVICES UTILIZATION AND RISK OF SURGERY ACROSS CHILDREN WITH INFLAMMATORY BOWEL DISEASE: A MULTIPROVINCE COHORT STUDY
20232 citationsauthor #3
Sa1787 PROTON PUMP INHIBITORS AND THE RISK OF INFLAMMATORY BOWEL DISEASE: A REAL WORLD POPULATION-BASED COHORT STUDY
20230 citationsauthor #6
A66 PROTON PUMP INHIBITORS AND THE RISK OF INFLAMMATORY BOWEL DISEASE: A REAL WORLD POPULATION-BASED COHORT STUDY
20230 citationsauthor #6
Sa1838 MAGIC IN IMAGINE: SURGERIES AND COMORBIDITIES ASSOCIATE WITH SPECIFIC CROHN'S DISEASE BEHAVIOUR IN A LARGE CANADIAN COHORT
20230 citationsauthor #13
961 TEMPORAL TRENDS AND RELATIVE RISKS OF INTESTINAL AND EXTRAINTESTINAL CANCERS IN PERSONS WITH INFLAMMATORY BOWEL DISEASES: A POPULATION-BASED STUDY FROM A LARGE CANADIAN PROVINCE
20232 citationsauthor #13
THE MEDICAL CARE PROCESS OF INFLAMMATORY BOWEL DISEASES IN CANADA: PERCEPTIONS OF PATIENTS AND PROVIDERS
20230 citationsauthor #4
Clinical efficacy and nocebo effect following non-medical biosimilar switch in patients with inflammatory bowel disease: A prospective observational study.
202313 citationsauthor #8
A191 NONALCOHOLIC FATTY LIVER DISEASE AND LIVER FIBROSIS INCREASE CARDIOVASCULAR RISK IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
20230 citationsauthor #5
634 DIETARY ASSOCIATIONS WITH METABOLITES IMPLICATED WITH CROHN'S DISEASE RISK
20230 citationsauthor #20
Nonalcoholic Fatty Liver Disease Increases Cardiovascular Risk in Inflammatory Bowel Diseases
20235 citationsauthor #5
962 EARLY LIFE EXPOSURE TO PARENTAL CROHN'S DISEASE IS ASSOCIATED WITH ALTERED GUT MICROBIOME COMPOSITION, IMPAIRED GUT PERMEABILITY, AND INCREASED RISK OF INCIDENT CROHN'S DISEASE
20232 citationsauthor #18
Immune response and barrier dysfunction-related proteomic signatures in preclinical phase of Crohn’s disease highlight earliest events of pathogenesis
202353 citationsauthor #16
A169 THE DIRECT COSTS OF INFLAMMATORY BOWEL DISEASE IN CANADA: A POPULATION-BASED ANALYSIS OF HISTORICAL AND CURRENT COSTS
20232 citationsauthor #5
A34 NONALCOHOLIC FATTY LIVER DISEASE AND LIVER FIBROSIS INCREASE CARDIOVASCULAR RISK IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
20230 citationsauthor #5
Mucosal Healing and Clinical Efficacy of Adalimumab in Small Intestinal Crohn’s Disease (SIMCHA Study): Final Results From a Prospective, Open-Label, Single-Arm Study
20234 citationsauthor #9
828 SERUM METABOLOMICS IDENTIFIES DYSREGULATED PATHWAYS AND POTENTIAL METABOLIC BIOMARKERS INVOLVED IN DEVELOPMENT OF CROHN'S DISEASE
20231 citationsauthor #16
OP29 Peri-natal exposure to parental Crohn’s disease is associated with impaired gut barrier, microbiome composition differences and increased risk of Crohn’s disease
20231 citationsauthor #18
A220 ONTARIO POPULATION TRENDS IN INTESTINAL AND EXTRA-INTESTINAL CANCERS OVER 25 YEARS AMONG PERSONS WITH INFLAMMATORY BOWEL DISEASES AND MATCHED CONTROLS
20230 citationsauthor #8
Proton pump inhibitors and the risk of inflammatory bowel disease: population-based cohort study
202318 citationsauthor #6
A210 THE BURDEN OF IBD HOSPITALIZATION IN CANADA: AN ASSESSMENT OF THE CURRENT AND FUTURE BURDEN IN A NATION-WIDE ANALYSIS
20231 citationsauthor #5
A198 THE LONG-TERM IMPACT OF ENVIRONMENTAL EXPOSURES ON HOST HEALTH AND THE RISK FACTORS OF CROHN'S DISEASE
20230 citationsauthor #17
Sa1777 HOSPITALIZATION RATES FOR INFLAMMATORY BOWEL DISEASE ARE DECREASING OVER TIME: A POPULATION-BASED COHORT STUDY
20230 citationsauthor #10
A35 FORECASTING THE INCIDENCE AND PREVALENCE OF INFLAMMATORY BOWEL DISEASE: A CANADIAN NATION-WIDE ANALYSIS
20235 citationsauthor #5
Mo1542: COMPARED EFFICACY OF USTEKINUMAB AND ANTI-TNF AGENTS AS FIRST-LINE BIOLOGICAL THERAPY IN LUMINAL CROHN’S DISEASE: A TWO-CENTER RETROSPECTIVE STUDY.
20220 citationsauthor #8
P524 Compared efficacy of ustekinumab and anti-TNF agents as first-line biological therapy in luminal Crohn’s disease
20220 citationsauthor #8
A150 ASSOCIATION BETWEEN SERUM USTEKINUMAB CONCENTRATIONS AND ENDOSCOPIC DISEASE ACTIVITY IN CROHN’S DISEASE
20220 citationsauthor #5
Author Correction: Somatic mosaicism and common genetic variation contribute to the risk of very-early-onset inflammatory bowel disease
20220 citationsauthor #244
Increased Prevalence of Myocardial Infarction and Stable Stroke Proportions in Patients with Inflammatory Bowel Diseases in Quebec in 1996–2015
20228 citationsauthor #9
Adherence to Objective Therapeutic Monitoring and Outcomes in Patients with Inflammatory Bowel Disease with Adalimumab Treatment. A Real-world Prospective Study.
20224 citationsauthor #12
793: ENVIRONMENTAL FACTORS ASSOCIATED WITH RISK OF CROHN'S DISEASE DEVELOPMENT IN A PROSPECTIVE COHORT OF HEALTHY FIRST-DEGREE RELATIVES OF CD PATIENTS
20221 citationsauthor #15
Sa1557: FORECASTING THE INCIDENCE AND PREVALENCE OF IBD: A CANADIAN NATION-WIDE ANALYSIS
20224 citationsauthor #5
Large-scale sequencing identifies multiple genes and rare variants associated with Crohn’s disease susceptibility
2022130 citationsauthor #17
P451 Evaluating drug sustainability, efficacy and safety of biologic agents in elderly patients with Inflammatory Bowel Disease: a single center retrospective study
20220 citationsauthor #12
P582 Association between serum ustekinumab concentrations and endoscopic disease activity in Crohn’s disease
20220 citationsauthor #5
DOP25 Clinical outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease
20220 citationsauthor #6
Comparative Effectiveness of Ustekinumab and Anti-TNF Agent as First-Line Biological Therapy in Luminal Crohn's Disease: A Retrospective Study From 2 Referral Centers.
202215 citationsauthor #8
Prostaglandins and calprotectin are genetically and functionally linked to the Inflammatory Bowel Diseases
202210 citationsauthor #9
P318 Safety of Biological Therapies in Elderly IBD: a Systematic Review and Meta-analysis
20222 citationsauthor #9
Tu1441: EVALUATING DRUG SUSTAINABILITY, EFFICACY AND SAFETY OF BIOLOGIC AGENTS IN ELDERLY PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A SINGLE CENTER RETROSPECTIVE STUDY
20220 citationsauthor #12
Su1571: SAFETY OF BIOLOGICAL THERAPIES IN ELDERLY IBD: A SYSTEMATIC REVIEW AND META-ANALYSIS
20220 citationsauthor #8
Impact of Endoscopic and Histologic Activity on Disease Relapse in Ulcerative Colitis
202220 citationsauthor #10
IBD-associated G protein-coupled receptor 65 variant compromises signalling and impairs key functions involved in inflammation.
202213 citationsauthor #7
Safety of Biological Therapies in Elderly Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis
202216 citationsauthor #8
A180 CLINICAL OUTCOMES OF COVID-19 AND IMPACT ON DISEASE COURSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
20220 citationsauthor #6
Mo1566: MUCOSAL HEALING AND CLINICAL REMISSION AFTER TREATMENT WITH ADALIMUMAB IN SMALL INTESTINAL CROHN’S DISEASE (SIMCHA STUDY): FINAL RESULTS FROM A PROSPECTIVE, OPEN-LABEL, SINGLEARM STUDY
20220 citationsauthor #5
Effectiveness, safety, and drug sustainability of biologics in elderly patients with inflammatory bowel disease: A retrospective study
20228 citationsauthor #12
P321 Mucosal Healing and Clinical remission after Treatment with Adalimumab in Small Intestinal Crohn’s Disease (SIMCHA study): final results from a prospective, open-label, single-arm study
20220 citationsauthor #7
A143 SAFETY OF BIOLOGICAL THERAPIES IN ELDERLY IBD: A SYSTEMATIC REVIEW
20220 citationsauthor #6
Hospitalization With Clostridioides difficile in Pediatric Inflammatory Bowel Disease: a Population-Based Study
20221 citationsauthor #4
Sequencing of over 100,000 individuals identifies multiple genes and rare variants associated with Crohns disease susceptibility
20218 citationsauthor #17
DOP18 UCEIS is associated with PRO2, partial Mayo and SCCAI remission in UC: Final results from a prospective study
20210 citationsauthor #8
Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Epidemiology—The Trends of Disease Over Time
20210 citationsauthor #4
Anti-microbial antibody response is associated with future onset of Crohn's disease independent of biomarkers of altered gut barrier function, subclinical inflammation, and genetic risk.
202155 citationsauthor #15
Inflammatory Bowel Disease Increases the Risk of Venous Thromboembolism in Children: A Population-Based Matched Cohort Study
202128 citationsauthor #2
Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: COVID-19 Vaccines—Biology, Current Evidence and Recommendations
20215 citationsauthor #10
Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Mental Health and Quality of Life
20216 citationsauthor #5
Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Children and Expectant Mothers With Inflammatory Bowel Disease
20214 citationsauthor #8
Su440 REAL-WORLD TIGHT OBJECTIVE MONITORING WITH ADALIMUMAB LEADS TO EARLIER DOSE OPTIMIZATION AND HIGHER CLINICAL REMISSION RATES AT 12 MONTHS.
20210 citationsauthor #13
I-wave Transcutaneous Thermotherapy for the Treatment of Benign Prostate Hypertrophy and Pelvic Dysfunction in Men
20210 citationsauthor #1
Serum Analyte Profiles Associated With Crohn's Disease and Disease Location.
202123 citationsauthor #18
Assessing adherence to objective disease monitoring and outcomes with adalimumab in a real-world IBD cohort.
20216 citationsauthor #13
Cystitis in Women: Focus
20210 citationsauthor #1
Serum Analyte Profiles Associated With Crohn's Disease and Disease Location.
202123 citationsauthor #6
Functional screen of inflammatory bowel disease genes reveals key epithelial functions
20211 citationsauthor #18
Patient-Reported Outcome and Clinical Scores Are Equally Accurate in Predicting Mucosal Healing in Ulcerative Colitis: A Prospective Study
20219 citationsauthor #8
Patient Perspectives of IBD Care and Services: An Integral Part of a Pan-Canadian Quality Improvement Initiative
202111 citationsauthor #10
Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 & Inflammatory Bowel Disease in Canada: A Knowledge Translation Strategy
20211 citationsauthor #6
Fucosyltransferase 2 Mutations Are Associated With a Favorable Clinical Course in Crohn’s Disease
20213 citationsauthor #9
P119 There is minimal agreement on the recognition of deep ulcers as seen on endoscopy in patients with Inflammatory Bowel Disease: a national survey
20210 citationsauthor #5
Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Executive Summary
20215 citationsauthor #5
Anti-TNF Therapy and the Risk of Herpes Zoster Among Patients With Inflammatory Bowel Disease.
20215 citationsauthor #2
Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Health Care Delivery During the Pandemic and the Future Model of Inflammatory Bowel Disease Care
20212 citationsauthor #14
P552 Assessing adherence to objective disease monitoring and outcomes with adalimumab in a real-world IBD cohort
20210 citationsauthor #13
Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Seniors With IBD
20212 citationsauthor #6
Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Risk Factors and Medications
20213 citationsauthor #6
Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease
202126 citationsauthor #6
P512 Efficacy of tofacitinib for the treatment of moderate-to-severe ulcerative colitis: real-world data
20204 citationsauthor #4
Novel Negative Pressure Box for Aerosol Protection During Upper Endoscopy: A Brief Report on Safety and Barrier Performance.
20201 citationsauthor #6
Benefits of implementing a rapid access clinic in a high-volume inflammatory bowel disease center: Access, resource utilization and outcomes
202015 citationsauthor #13
P807 UCEIS is associated with PRO2, partial Mayo and SCCAI remission in UC: preliminary results from a prospective study
20201 citationsauthor #7
A64 HOSPITALIZATION IN INFLAMMATORY BOWEL DISEASE: A POPULATION-BASED COMPARISON OF DEFINITIONS
20200 citationsauthor #4
Poor Drug Sustainability in Inflammatory Bowel Disease Patients in Clinical Remission on Thiopurine Monotherapy
20205 citationsauthor #5
Mo1831 UCEIS IS ASSOCIATED WITH PRO2, PARTIAL MAYO AND SCCAI REMISSION IN UC: PRELIMINARY RESULTS FROM A PROSPECTIVE STUDY
20200 citationsauthor #7
P841 Evaluation of gut microbiota composition in NAFLD with UC pancolitis in clinical remission: a pilot study
20200 citationsauthor #10
P570 The burden of anaemia remains significant over time in patients with inflammatory bowel disease at a tertiary referral centre
20200 citationsauthor #10
P364 Patient reported outcomes, partial MAYO score and SCCAI are equally accurate in predicting mucosal healing in UC: final results form a prospective study
20201 citationsauthor #8
No Change in Surgical and Hospitalization Trends Despite Higher Exposure to Anti-Tumor Necrosis Factor in Inflammatory Bowel Disease in the Québec Provincial Database From 1996 to 2015.
202017 citationsauthor #10

TIMELINE

1995 20 citations

1996 0 citations

1997 31 citations

1998 2 citations

1999 0 citations

2000 536 citations

2001 1,729 citations

2002 339 citations

2003 396 citations

2004 97 citations

2005 173 citations

2006 3,445 citations

2007 161 citations

2008 3,420 citations

2009 1,444 citations

2010 31 citations

2011 219 citations

2012 535 citations

2013 564 citations

2014 1,742 citations

2015 1,255 citations

2016 1,256 citations

2017 732 citations

2018 1,729 citations

2019 857 citations

2020 494 citations

2021 203 citations

2022 232 citations

2023 157 citations

2025 0 citations

Unknown 9 citations

A. Bitton

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT